Publicaciones en colaboración con investigadores/as de Hospital Morales Meseguer (27)

2024

  1. Induction avelumab followed by chemoimmunotherapy and maintenance versus chemotherapy alone as first-line therapy in cis-ineligible metastatic urothelial carcinoma (INDUCOMAIN): a randomized phase II study

    ESMO Open, Vol. 9, Núm. 9

  2. Prospective study of predictors for anxiety, depression, and somatization in a sample of 1807 cancer patients

    Scientific reports, Vol. 14, Núm. 1, pp. 3188

2021

  1. Erratum to “Critical reappraisal of phase III trials with immune checkpoint inhibitors in non-proportional hazards settings” [Eur J Cancer 136 (September 2020) 159−168] (European Journal of Cancer (2020) 136 (159–168), (S0959804920303300), (10.1016/j.ejca.2020.06.003))

    European Journal of Cancer

2020

  1. A Trial of Lopinavir-Ritonavir in Covid-19

    The New England journal of medicine

  2. Critical reappraisal of phase III trials with immune checkpoint inhibitors in non-proportional hazards settings

    European Journal of Cancer, Vol. 136, pp. 159-168

  3. Does active smoking worsen Covid-19?

    European Journal of Internal Medicine

  4. Palbociclib combined with endocrine therapy in heavily pretreated HR+/HER2- advanced breast cancer patients: Results from the compassionate use program in Spain (PALBOCOMP)

    Breast, Vol. 54, pp. 286-292

  5. Real-world effectiveness of dual HER2 blockade with pertuzumab and trastuzumab for neoadjuvant treatment of HER2-positive early breast cancer (The NEOPETRA Study)

    Breast Cancer Research and Treatment, Vol. 184, Núm. 2, pp. 469-479

2019

  1. Efficacy and safety results from GEICO 1205, a randomized phase II trial of neoadjuvant chemotherapy with or without bevacizumab for advanced epithelial ovarian cancer

    International Journal of Gynecological Cancer, Vol. 29, Núm. 6, pp. 1050-1056

  2. Evaluating radiological response in pancreatic neuroendocrine tumours treated with sunitinib: comparison of Choi versus RECIST criteria (CRIPNET_ GETNE1504 study)

    British Journal of Cancer, Vol. 121, Núm. 7, pp. 537-544

2018

  1. The prognostic impact of additional intrathoracic findings in patients with cancer-related pulmonary embolism

    Clinical and Translational Oncology, Vol. 20, Núm. 2, pp. 230-242

  2. Top ten errors of statistical analysis in observational studies for cancer research

    Clinical and Translational Oncology, Vol. 20, Núm. 8, pp. 954-965

2017

  1. A definition for aggressive disease in patients with HER-2 negative metastatic breast cancer: an expert consensus of the Spanish Society of Medical Oncology (SEOM)

    Clinical and Translational Oncology, Vol. 19, Núm. 5, pp. 616-624

  2. Capecitabine and temozolomide in grade 1/2 neuroendocrine tumors: A Spanish multicenter experience

    Future Oncology, Vol. 13, Núm. 7, pp. 615-624

  3. Chronic opioid therapy in long-term cancer survivors

    Clinical and Translational Oncology, Vol. 19, Núm. 2, pp. 236-250

  4. Clinical features and short-term outcomes of cancer patients with suspected and unsuspected pulmonary embolism: The EPIPHANY study

    European Respiratory Journal, Vol. 49, Núm. 1

  5. Performance of the clinical index of stable febrile neutropenia (CISNE) in different types of infections and tumors

    Clinical and Translational Oncology, Vol. 19, Núm. 3, pp. 386-395

  6. Predicting serious complications in patients with cancer and pulmonary embolism using decision tree modelling: The EPIPHANY Index

    British Journal of Cancer, Vol. 116, Núm. 8, pp. 994-1001

  7. Prognostic significance of performing universal HER2 testing in cases of advanced gastric cancer

    Gastric Cancer, Vol. 20, Núm. 3, pp. 465-474

  8. Prognostic value of computed tomography pulmonary angiography indices in patients with cancer-related pulmonary embolism: Data from a multicenter cohort study

    European Journal of Radiology, Vol. 87, pp. 66-75